| Previous Close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.08 x 0 |
| Ask | 0.09 x 0 |
| Day's Range | 0.0800 - 0.0800 |
| 52 Week Range | 0.0700 - 0.3500 |
| Volume | 8,178 |
| Avg. Volume | 1,353,135 |
| Market Cap | 9.17M |
| Beta (3Y Monthly) | 3.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
VANCOUVER, British Columbia, Dec. 06, 2018 -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer.
NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, Frankfurt: 1N9) is pleased to provide a further update on its previously announced non-binding letter of intent (“LOI”) between the Company and Naturally Splendid USA Ltd. ("Naturally Splendid") (TSX-V: NSP, OTCQB: NSPDF). This new binding LOI signifies the successful completion of a sublingual HempOmega® tablet using NeutriSci’s IP and technology, as well as a sublingual tablet combining HempOmega® and CBD (cannabidiol). A definitive agreement between the parties will follow in the coming weeks.
NATURALLY SPLENDID ENTERPRISES LTD. (NSP.V)(NSPDF) (“Naturally Splendid” or “NSE” or the “ Company” or “Naturally Splendid USA”) is pleased to provide a further update on its previously announced non-binding Letter of Intent (“LOI”) between Naturally Splendid USA Ltd. and NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), together the (“Parties”). Naturally Splendid USA and NeutriSci are pleased to announce the extension and addition of binding terms to the previously announced LOI. This new binding LOI signifies the successful completion of an agreement to produce a sublingual HempOmega® tablet using NeutriSci’s IP and technology, as well as a sublingual tablet combining HempOmega® and CBD (cannabidiol).
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci") the innovator and pioneer behind neuenergy®, is pleased to announce the filing of a new U.S. provisional patent application (United States Provisional Patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds.Cannabinoids ...
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci") and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) ("Lexaria") are pleased to announce that they have revised their joint venture agreement such that NeutriSci now owns 100% of Ambarii Trade Corporation ("Ambarii"), and Lexaria has granted to NeutriSci, an Intellectual Property License and Supply Agreement (the "License Agreement") for the manufacturing and sale of CBD ...
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / February 26, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces ...
NeutriSci International Inc. , the innovator and pioneer behind neuenergy®, is pleased to announce a one-year sponsorship deal with Canadian and International tennis...
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci"), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. ("Scientus Pharma"). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing ...